NBIX peer analysis
Neurocrine Biosciences (NBIX) against its competitors: price, today's move, 1-year return and market value side by side.
NBIX and its peers
| Company | Price | Today | 1-year return | Market cap |
|---|---|---|---|---|
| ACAD Acadia Pharmaceuticals | $20.47 | -0.58% | -9.98% | $3.55B |
| AXSM Axsome Therapeutics | $136.07 | -5.79% | 2.19% | $7.57B |
| BHVN Biohaven | $15.14 | -1.78% | -12.91% | $2.33B |
| GHRS GH Research | $20.86 | -2.98% | 66.35% | – |
| JAZZ Jazz Pharmaceuticals | $214.64 | -0.62% | 57.48% | $14.02B |
| NMRA Neumora Therapeutics | $0.37 | -5.43% | -87.47% | – |
| RAPP Rapport Therapeutics | $25.10 | 0.20% | -6.62% | – |
| SUPN Supernus Pharmaceuticals | $41.92 | 0.19% | -25.81% | $2.44B |
| VNDA Vanda Pharmaceuticals | $3.79 | -6.42% | -12.27% | $229.18M |
| NBIX Neurocrine Biosciences | $156.00 | 6.78% | 13.01% | $14.85B |
- NBIX's peers: ACAD (Acadia Pharmaceuticals), AXSM (Axsome Therapeutics), BHVN (Biohaven), GHRS (GH Research), JAZZ (Jazz Pharmaceuticals), NMRA (Neumora Therapeutics), RAPP (Rapport Therapeutics), SUPN (Supernus Pharmaceuticals).
Updated 2026-11-02 23:14 UTC